NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — Hudson Acquisition I Corp. (the “Company” or “Hudson”) (Nasdaq:HUDA), today announced that it has entered into a letter of intent (the “LOI”) with a target company (the “Target Company”) for a potential business combination (the “Acquisition”). The LOI is not a binding agreement, and it outlines the preliminary terms of the Acquisition and the transactions contemplated herein. The Target Company is a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses.

Read more at globenewswire.com

Related news for (HUDAU)

    NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.